Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial

por Kudrow, David, Cady, Roger K., Allan, Brent, Pederson, Susan M., Hirman, Joe, Mehta, Lahar R., Schaeffler, Barbara A.
Publicado 2021

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)

por Ashina, Messoud, Saper, Joel, Cady, Roger, Schaeffler, Barbara A, Biondi, David M, Hirman, Joe, Pederson, Susan, Allan, Brent, Smith, Jeff
Publicado 2020

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2

por Lipton, Richard B., Goadsby, Peter J., Smith, Jeff, Schaeffler, Barbara A., Biondi, David M., Hirman, Joe, Pederson, Susan, Allan, Brent, Cady, Roger
Publicado 2020